Notice for enasidenib (Celgene Pty Ltd)
Active ingredients
enasidenib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Tablet, film-coated
Indication
For the treatment of patients with acute myeloid leukaemia with an isocitrate dehydrogenase-2 (IDH2) mutation.